Published in Curr Med Res Opin on May 01, 2007
Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med (2012) 3.49
Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev (2008) 2.13
Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol (2009) 1.76
Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73
From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev (2008) 1.65
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol (2010) 1.10
IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine (2013) 0.95
Ustekinumab: differential use in psoriasis. Clin Cosmet Investig Dermatol (2011) 0.91
Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells. Proteins (2013) 0.86
The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases. Arch Immunol Ther Exp (Warsz) (2015) 0.82
Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. Int J Cell Biol (2016) 0.79
Ustekinumab in the therapy of chronic plaque psoriasis. Biologics (2009) 0.79
Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis (2013) 0.79
Potential role of ustekinumab in the treatment of chronic plaque psoriasis. Biologics (2010) 0.78
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann Rheum Dis (2017) 0.77
Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis. CPT Pharmacometrics Syst Pharmacol (2013) 0.76
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manag (2010) 0.75
Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis. Rheumatol Ther (2015) 0.75
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy. Drug Des Devel Ther (2016) 0.75
Ustekinumab for the treatment of psoriatic arthritis: an update. Clin Cosmet Investig Dermatol (2014) 0.75
Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study. Clin Rheumatol (2017) 0.75
Use of indoor tanning facilities by white adolescents in the United States. Arch Pediatr Adolesc Med (2003) 3.16
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol (2004) 2.96
Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol (2005) 2.49
Fusobacterium nucleatum induces premature and term stillbirths in pregnant mice: implication of oral bacteria in preterm birth. Infect Immun (2004) 2.47
Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol (2008) 2.23
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
Prognosis of patients with transected melanomas. Dermatol Surg (2013) 2.04
Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol (2004) 1.81
IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol (2009) 1.77
Sunlight, tanning booths, and vitamin D. J Am Acad Dermatol (2005) 1.68
Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies. Toxicol Appl Pharmacol (2007) 1.64
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol (2007) 1.62
Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol (2008) 1.58
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol (2006) 1.54
Oxaliplatin: a review of evolving concepts. Cancer Invest (2002) 1.47
High ultraviolet A protection affords greater immune protection confirming that ultraviolet A contributes to photoimmunosuppression in humans. J Invest Dermatol (2003) 1.47
Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther (2014) 1.42
Usefulness of flow cytometry in the diagnosis of mycosis fungoides. J Am Acad Dermatol (2007) 1.41
Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis. Am J Pathol (2009) 1.32
Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J Med Chem (2014) 1.27
Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J Immunol (2011) 1.26
Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol (2013) 1.20
Interaction of Candida albicans with adherent human peripheral blood mononuclear cells increases C. albicans biofilm formation and results in differential expression of pro- and anti-inflammatory cytokines. Infect Immun (2007) 1.16
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther (2005) 1.13
Ultraviolet immunosuppression: mechanisms and consequences. Dermatol Clin (2006) 1.09
Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol (2002) 1.08
Computerized interactive educational tools used to improve use of sun-protective clothing and sunscreen: a randomized controlled study. Arch Dermatol (2012) 1.08
Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial. Lasers Surg Med (2010) 1.07
Improvement in Patient Performance of Skin Self-examinations After Intervention With Interactive Education and Telecommunication Reminders: A Randomized Controlled Study. Arch Dermatol (2012) 1.05
Apoptosis mechanisms related to the increased sensitivity of Jurkat T-cells vs A431 epidermoid cells to photodynamic therapy with the phthalocyanine Pc 4. Photochem Photobiol (2008) 1.02
Quantification of human beta-defensin-2 and -3 in body fluids: application for studies of innate immunity. Clin Chem (2007) 1.01
Inhibition of monocytic interleukin-12 production by Candida albicans via selective activation of ERK mitogen-activated protein kinase. Infect Immun (2004) 1.01
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol (2011) 0.99
Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol (2012) 0.99
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res (2007) 0.99
Modification of surface properties of biomaterials influences the ability of Candida albicans to form biofilms. Appl Environ Microbiol (2005) 0.99
Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool. J Invest Dermatol (2011) 0.98
Regulation generation: the suppressive functions of human regulatory T cells. Crit Rev Immunol (2012) 0.98
Factors that affect skin aging: a cohort-based survey on twins. Arch Dermatol (2009) 0.98
The sensitivity of Medicare data for identifying incident cases of invasive melanoma (United States). Cancer Causes Control (2004) 0.97
Topical application of green and white tea extracts provides protection from solar-simulated ultraviolet light in human skin. Exp Dermatol (2009) 0.97
Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol (2011) 0.96
IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine (2013) 0.95
Signal peptide cleavage is essential for surface expression of a regulatory T cell surface protein, leucine rich repeat containing 32 (LRRC32). BMC Biochem (2011) 0.95
Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat (2006) 0.94
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol (2010) 0.94
Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding. Clin Cancer Res (2005) 0.93
Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation (2003) 0.93
Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res (2013) 0.92
Epithelial cell-derived antimicrobial peptides are multifunctional agents that bridge innate and adaptive immunity. Periodontol 2000 (2010) 0.92
Photodynamic therapy with Pc 4 induces apoptosis of Candida albicans. Photochem Photobiol (2011) 0.92
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update. Ann N Y Acad Sci (2012) 0.91
Circumscribed palmo-plantar hypokeratosis: a disease with two subtypes. J Invest Dermatol (2008) 0.91
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci (2011) 0.90
Cutaneous hypersensitivity to Candida albicans in idiopathic vulvodynia. Contact Dermatitis (2005) 0.90
Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential. Hum Pathol (2003) 0.90
Psoriasis patients exhibit impairment of the high potency CCR5(+) T regulatory cell subset. Clin Immunol (2013) 0.89
Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol (2009) 0.89
Fusobacterium nucleatum-associated beta-defensin inducer (FAD-I): identification, isolation, and functional evaluation. J Biol Chem (2010) 0.88
The yin and yang of human Beta-defensins in health and disease. Front Immunol (2012) 0.88
Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol (2009) 0.88
Preliminary clinical and pharmacologic investigation of photodynamic therapy with the silicon phthalocyanine photosensitizer pc 4 for primary or metastatic cutaneous cancers. Front Oncol (2011) 0.87
Anti-angiogenic effects of epigallocatechin-3-gallate in human skin. Int J Clin Exp Pathol (2010) 0.87
Alefacept in the treatment of psoriasis. Clin Dermatol (2008) 0.86
Effect of topical vitamin D analogue on in vivo contact sensitization. Arch Dermatol (2006) 0.86
Final results of the ReoPro readministration registry. Am J Cardiol (2004) 0.85
A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin (2006) 0.85
Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology (Oxford) (2013) 0.85
Smoking and skin aging in identical twins. Arch Dermatol (2007) 0.85
Photodynamic therapy in dermatology: current concepts in the treatment of skin cancer. Expert Rev Anticancer Ther (2005) 0.85